Reimbursed Care Access in Azerbaijan

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Internationally the active chemicals are conventionally controlled under the 1971 UN Psychotropic Convention, and there is no indication in Azerbaijani public regulatory sources that psilocybin has been approved or reimbursed for medical use in Azerbaijan. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Azerbaijani law-enforcement and national security services publicly report seizures and counter-narcotics operations targeting MDMA/ecstasy, indicating active criminal enforcement rather than medical availability. # #.

No publicly available Azerbaijani regulatory or reimbursement documentation was found showing authorization, registration, or routine reimbursement for esketamine (Spravato) as of February 20, 2026. Azerbaijan’s Ministry of Health lists ketamine among medicines used in hospitals, but national medicine lists and 'medicines under special control' publications reviewed do not include a marketed esketamine nasal-spray product or an approval notice for that specific formulation; therefore esketamine is not known to be approved or reimbursed for treatment-resistant depression in routine care in Azerbaijan and would, if used, likely be limited to investigational use or importation under exceptional procedures. # #.

Ketamine (typically as injectable ketamine hydrochloride) is an accepted medicinal anesthetic and analgesic in Azerbaijani hospitals and appears on official facility medicine lists distributed by the Ministry of Health; historical ministry publications list ketamine on a catalogue of medicines provided in hospital settings, indicating its routine medical availability and use. This means ketamine is available for medical indications (anesthesia, analgesia, and in some countries off‑label psychiatric use), administered within healthcare facilities under clinician oversight, and is included in state hospital formularies rather than being an illicit-only substance in practice. #.

Regulatory/coverage context: Azerbaijan’s Ministry of Health and its Board define lists of medicines that are provided in state facilities and those under special control; ketamine’s presence on a Ministry list demonstrates institutional availability and supply in hospitals rather than a legalized ambulatory, reimbursed psychiatric program for psychedelic-assisted therapy. There is no publicly available official Azerbaijani guidance or reimbursement policy documents identified that establish ketamine for labeled psychiatric indications (e.g., intranasal/esketamine programs for treatment-resistant depression) or that define insurance reimbursement frameworks for psychiatric off-label ketamine in outpatient mental health clinics. Institutions procuring and administering ketamine do so under existing hospital procurement and clinical-use regulations; private clinics may offer ketamine infusions under clinicians’ discretion but widespread structured reimbursement for psychiatric use was not identified in public sources. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No public Azerbaijani regulatory approval or reimbursement pathways were identified for DMT-containing therapies; possession or trafficking is governed by national narcotics and criminal statutes. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No evidence of legal medical frameworks or reimbursement for 5‑MeO‑DMT in Azerbaijan was found in public regulatory sources. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no indication of a national medical authorization or reimbursement framework for ibogaine in Azerbaijan; any use would be experimental and outside routine medical coverage. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations that contain DMT (the primary controlled constituent) would fall under national controls and be subject to prohibition and enforcement; there is no recognized medical program or reimbursement for ayahuasca in Azerbaijan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline-containing materials and the pure compound are not documented as legally authorized for medical treatment or reimbursement in Azerbaijan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C-series compounds are generally treated as illicit designer/psychotropic substances under criminal narcotics provisions, and no medical authorization or reimbursement framework exists for them in Azerbaijan. #.